Gary Fanjiang, MD, vice president of Biosimilars Global Development, Amgen, discusses the development of biosimilars and some of the clinical considerations related to their use.
Sponsored Content by Amgen
Advertisement
Articles by Sponsored Content by Amgen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Next-Generation CTLA-4 Targeting Frames Post-Immunotherapy Squamous NSCLC Management
2
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
3
Carotuximab Plus Apalutamide Improves PFS in mCRPC
4
Dr Dhakal on the Investigation of Novel CAR T-Cell Therapy Approaches in Myeloma
5